Drug Profile
GC 4403
Alternative Names: GC-4403Latest Information Update: 21 Apr 2016
Price :
$50
*
At a glance
- Originator Galera Therapeutics
- Class Antifibrotics; Antineoplastics; Chemoprotectants; Small molecules
- Mechanism of Action Antioxidants; Superoxide dismutase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Fibrosis; Stomatitis
Most Recent Events
- 11 Dec 2012 Phase-I clinical trials in Stomatitis (in volunteers) in USA (unspecified route)
- 11 Dec 2012 Preclinical trials in Cancer in USA (unspecified route)
- 11 Dec 2012 Preclinical trials in Fibrosis in USA (unspecified route)